ArticleCancer medicine2026
Initial Site of Metastasis Influences Prognosis in Pancreatic Ductal Adenocarcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive malignancy. Prior studies suggest that the initial site of metastasis may impact prognosis. This study investigates whether overall survival in mPDAC patients differs between patients first presenting with lung metastases versus those presenting with liver metastases.
methodsThis retrospective analysis utilized the multi-institutional TriNetX database, identifying patients with histologically diagnosed PDAC who initially presented with either liver or lung metastases. Demographic, histologic, and outcome data were collected and analyzed. Patients were matched 1:1 using a nearest neighbor propensity score (PS) algorithm, and Kaplan-Meier survival analyses were performed. Cox regression was also used to further validate the results of the PS matching.
resultsA total of 6256 patients were identified, including 5390 patients presenting with liver and 866 patients presenting with lung metastases at diagnosis. The mean age was 66.6 ± 10.5, the male-to-female ratio was 54%:46%, the mean carbohydrate-antigen (CA) 19-9 level was 1309 ± 2078 ng/mL, the mean carcinoembryonic-antigen (CEA) level was 117 ± 1044 U/mL. Propensity score matching yielded 848 matched pairs. Median survival from time of metastatic diagnosis was significantly longer for patients with lung metastases compared to liver (377 vs. 195 days, p < 0.0001). Cox regression identified several factors associated with increased risk of death: older age, obesity, malnutrition, and elevated CEA or CA 19-9. Additionally, initial lung metastases were associated with decreased risk of death (HR = 0.61, p < 0.0001).
conclusionInitial presentation with lung metastases appears to be associated with improved survival outcomes as compared to initial presentation with liver metastases in patients with mPDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.